In particular, we demonstrate that PAD2 is important for the development of RA-ILD by promoting a profibrotic phenotype in RA-ILD fibroblasts, independent of ACPA, that is mitigated by treatment with SDC2. This evidence concerns the gene PADI2 and rheumatoid arthritis.